Walter Reinisch

P010 Precision Dosing Tool Forecasts Trough Infliximab and Associates With Disease Status in Inflammatory Bowel Diseases

BACKGROUND: Substantial inter- and intra-individual variability of infliximab (IFX) pharmacokinetics (PK) necessitates tailored dosing approaches. Here, we evaluated the perfo...

Thierry Dervieux ;

Christian Primas ;

John Panetta ;

Diane Mould ;

Alexander Eser ;

Walter Reinisch ;

12/15/2021

Rapid Symptomatic Remission in Patients With Ulcerative Colitis Treated With the Anti-MAdCAM-1 Antibody Ontamalimab: Results From TURANDOT and TURANDOT II

BACKGROUND: Treatment of ulcerative colitis (UC) aims to induce and maintain both endoscopic and symptomatic remission. While assessment of endoscopic remission is limited by timing of en...

Walter Reinisch ;

Silvio Danese ;

Xavier Hebuterne ;

Maria Kopocka ;

Dino Tarabar ;

Tomas Valasek ;

Milos Gregus ;

William J. Sandborn , MD;

Paul Hellstern ;

Kim Joo Sung ;

Miles Sparrow ;

Kenneth Gorelick ;

Michael Hoy ;

Martina Goetsch ;

12/12/2019

Extraintestinal Manifestations at Baseline, and Effect of Tofacitinib in Patients With Moderate to Severe Ulcerative Colitis in the OCTAVE Program

BACKGROUND: Extraintestinal manifestations (EIMs) occur in approximately one-third of patients with ulcerative colitis (UC) (1). Tofacitinib is an oral, small molecule JAK inhibitor for t...

Paulo Gustavo Kotze ;

David T. Rubin , MD;

Marcia Pinheiro ;

Gary R. Lichtenstein ;

Haiyun Fan ;

Walter Reinisch ;

Marc Fellmann ;

Irene Modesto ;

Nervin Lawendy ;

Eric Maller ;

Thomas Greuter ;

Stephen Vavricka ;